Integer Holdings: Citigroup maintains a 'Neutral' Rating, The Target Price is $75

Citigroup maintains 'Neutral' rating on Integer Holdings(ITGR).

The target price is $75, compare with $69 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-12-11	Citigroup	Maintains	Neutral	Neutral	$75	$69
2025-11-24	Truist Securities	Maintains	Buy	Buy	$86	$88

[Company Profile] Integer Holdings Corporation co-inventor of the first successful implanted pacemaker, founded Greatbatch in 1970. Greatbatch, Inc. is a Delaware corporation that was incorporated in 1997. The company had its initial public offering in 2000. The Company operates its company in two reportable segments – Greatbatch Medical and Electrochem Solutions (“Electrochem”). The company's customers include large multi-national original equipment manufacturers (“OEMs”). The Greatbatch Medical segment designs and manufactures medical devices and components primarily for the Cardiac Rhythm Management (“CRM”), Neuromodulation, Vascular Access and Orthopaedic markets. Additionally, Greatbatch Medical offers value-added assembly and design engineering services for products that incorporate Greatbatch Medical components. As a result of its strategy put in place over three years ago, Greatbatch Medical now offers its customers complete medical devices including design, development, manufacturing, regulatory submission and supporting worldwide distribution. This medical device strategy is being facilitated through the QiG Group and leverages the component technology of Greatbatch Medical and Electrochem in she company's core markets: Cardiovascular, Neuromodulation and Orthopaedic. Once the QiG Group designs and develops a medical device, it is manufactured by Greatbatch Medical.